Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
06. Mai 2024 11:16 ET | Achieve Life Sciences
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo   Cytisinicline treatment well tolerated with no serious adverse events...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
11. September 2023 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
07. September 2023 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
14. August 2023 16:00 ET | Achieve Life Sciences
Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE and VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast
01. August 2023 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
20. April 2023 08:00 ET | Achieve Life Sciences
First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study Supports Potential Broad Utilization of Cytisinicline for...